Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimizing Caffeine Therapy for Hypoxia in Preterm Neonates
NCT07262060Phase 2Recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- May 2026
- Primary completion
- Mar 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of caffeine in hypoxia, acute kidney injury (AKI), sponsored by University of Wisconsin–Madison. Started May 2026; status: recruiting.
02
Drugs
caffeine
03
Conditions
hypoxiaacute kidney injury (AKI)
Beyond the preview
Go deeper on NCT07262060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07262060.